Company Research Report: Prenosis, Inc.

Company Overview

• Name: Prenosis, Inc.

• Mission: Prenosis aims to empower clinicians to see individuals differently by equipping them with a deep understanding of each patient’s biology. Their mission centers around tailoring healthcare to an individual's biology, thereby improving outcomes in acute care.

• Founded: 2014

• Founders: No information is available.

• Key People:

• Bobby Reddy, Jr., Ph.D. - Co-Founder / CEO / Board Member

• Angela McFarland - Chief Financial Officer

• Carlos Lopez-Espina - SVP of Research & Development

• Robin Carver, RN, MSN, CIC - VP of Health System Management

• Brian Bray - VP of Technology

• Jay Kaminski - Head of Pharma Strategy

• Nathan I. Shapiro, MD, MPH - Head Advisor for Clinical Research

• Jim Sianis, B.S., PharmD, MBA - Executive Director of Business Development

• Headquarters: Chicago, Illinois

• Number of Employees: 36 employees (as seen on LinkedIn)

• Revenue: No information is available.

• Known For: Known for their Sepsis ImmunoScore™, an FDA De Novo authorized AI Diagnostic for Sepsis, aimed at diagnosing sepsis and predicting adverse outcomes.

Products

1. Immunix™ Precision Medicine Platform

• Description: Immunix™ is a precision medicine platform that creates and validates new precision medicine tools, influencing patient care in real-time. It is responsible for generating the world's largest biomarker-clinical dataset for infection in acute care using machine learning algorithms.

2. Sepsis ImmunoScore™

• Description: A cutting-edge AI-powered diagnostic tool that integrates biomarkers and clinical data for sepsis detection and prognosis.

• Key Features:

• FDA Authorized: The first-ever FDA De Novo authorized AI diagnostic for sepsis.

• Integration: Directly integrates into hospital Electronic Medical Records (EMRs) for seamless access.

• Parameters Used: Utilizes 22 diverse parameters to assess sepsis risk, not as an alert system but as a diagnostic tool producing four risk categories.

• Predictive Capabilities: Assists in predicting adverse outcomes within 24 hours, including ICU admission, mechanical ventilation, and vasopressor use.

Recent Developments

• New Products Launched: The Sepsis ImmunoScore™ was granted FDA De Novo marketing authorization on April 3, 2024, marking a significant achievement as the first AI tool for diagnosing sepsis.

• New Features: No information is available regarding recent feature additions.

• Partnerships:

• Roche Diagnostics: Prenosis entered a commercial distribution collaboration with Roche, facilitating the availability of the Sepsis ImmunoScore™ on the Roche navify® Algorithm Suite platform.

• Other Developments:

• On April 10, 2024, Prenosis announced the collaboration with Roche for wider distribution.

• The Sepsis ImmunoScore™'s FDA authorization was extensively covered by numerous media outlets, recognizing its breakthrough presence in hospitals for early sepsis detection.

Prenosis is at the forefront of leveraging artificial intelligence to transform acute care through precision diagnostics and real-time software integrations, reflecting its innovative edge in healthcare.